Cargando…

High-sensitivity troponin I with or without ultra-sensitive copeptin for the instant rule-out of acute myocardial infarction

BACKGROUND: The instant, single-sampling rule-out of acute myocardial infarction (AMI) is still an unmet clinical need. We aimed at testing and comparing diagnostic performance and prognostic value of two different single-sampling biomarker strategies for the instant rule-out of AMI. METHODS: From t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricci, Fabrizio, Neumann, Johannes T., Rübsamen, Nicole, Sörensen, Nils A., Ojeda, Francisco, Cataldo, Ivana, Zeller, Tanja, Schäfer, Sarina, Hartikainen, Tau S., Golato, Maria, Palermi, Stefano, Zimarino, Marco, Blankenberg, Stefan, Westermann, Dirk, De Caterina, Raffaele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395923/
https://www.ncbi.nlm.nih.gov/pubmed/36017085
http://dx.doi.org/10.3389/fcvm.2022.895421
_version_ 1784771810646032384
author Ricci, Fabrizio
Neumann, Johannes T.
Rübsamen, Nicole
Sörensen, Nils A.
Ojeda, Francisco
Cataldo, Ivana
Zeller, Tanja
Schäfer, Sarina
Hartikainen, Tau S.
Golato, Maria
Palermi, Stefano
Zimarino, Marco
Blankenberg, Stefan
Westermann, Dirk
De Caterina, Raffaele
author_facet Ricci, Fabrizio
Neumann, Johannes T.
Rübsamen, Nicole
Sörensen, Nils A.
Ojeda, Francisco
Cataldo, Ivana
Zeller, Tanja
Schäfer, Sarina
Hartikainen, Tau S.
Golato, Maria
Palermi, Stefano
Zimarino, Marco
Blankenberg, Stefan
Westermann, Dirk
De Caterina, Raffaele
author_sort Ricci, Fabrizio
collection PubMed
description BACKGROUND: The instant, single-sampling rule-out of acute myocardial infarction (AMI) is still an unmet clinical need. We aimed at testing and comparing diagnostic performance and prognostic value of two different single-sampling biomarker strategies for the instant rule-out of AMI. METHODS: From the Biomarkers in Acute Cardiac Care (BACC) cohort, we recruited consecutive patients with acute chest pain and suspected AMI presenting to the Emergency Department of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany. We compared safety, effectiveness and 12-month incidence of the composite endpoint of all-cause death and myocardial infarction between (i) a single-sampling, dual-marker pathway combining high-sensitivity cardiac troponin I (hs-cTnI) and ultra-sensitive copeptin (us-Cop) at presentation (hs-cTnI ≤ 27 ng/L, us-Cop < 10 pmol/L and low-risk ECG) and (ii) a single-sampling pathway based on one-off hs-cTnI determination at presentation (hs-cTnI < 5 ng/L and low-risk ECG). As a comparator, we used the European Society of Cardiology (ESC) 0/1-h dual-sampling algorithm. RESULTS: We enrolled 1,136 patients (male gender 65%) with median age of 64 years (interquartile range, 51–75). Overall, 228 (20%) patients received a final diagnosis of AMI. The two single-sampling instant rule-out pathways yielded similar negative predictive value (NPV): 97.4% (95%CI: 95.4–98.7) and 98.7% (95%CI: 96.9–99.6) for dual-marker and single hs-cTnI algorithms, respectively (P = 0.11). Both strategies were comparably safe as the ESC 0/1-h dual-sampling algorithm and this was consistent across subgroups of early-comers, low-intermediate risk (GRACE-score < 140) and renal dysfunction. Despite a numerically higher rate of false-negative results, the dual-marker strategy ruled-out a slightly but significantly higher percentage of patients compared with single hs-cTnI determination (37.4% versus 32.9%; P < 0.001). There were no significant between-group differences in 12-month composite outcome. CONCLUSIONS: Instant rule-out pathways based on one-off determination of hs-cTnI alone or in combination with us-Cop are comparably safe as the ESC 0/1 h algorithm for the instant rule-out of AMI, yielding similar prognostic information. Instant rule-out strategies are safe alternatives to the ESC 0/1 h algorithm and allow the rapid and effective triage of suspected AMI in patients with low-risk ECG. However, adding copeptin to hs-cTn does not improve the safety of instant rule-out compared with the single rule-out hs-cTn at very low cut-off concentrations.
format Online
Article
Text
id pubmed-9395923
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93959232022-08-24 High-sensitivity troponin I with or without ultra-sensitive copeptin for the instant rule-out of acute myocardial infarction Ricci, Fabrizio Neumann, Johannes T. Rübsamen, Nicole Sörensen, Nils A. Ojeda, Francisco Cataldo, Ivana Zeller, Tanja Schäfer, Sarina Hartikainen, Tau S. Golato, Maria Palermi, Stefano Zimarino, Marco Blankenberg, Stefan Westermann, Dirk De Caterina, Raffaele Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: The instant, single-sampling rule-out of acute myocardial infarction (AMI) is still an unmet clinical need. We aimed at testing and comparing diagnostic performance and prognostic value of two different single-sampling biomarker strategies for the instant rule-out of AMI. METHODS: From the Biomarkers in Acute Cardiac Care (BACC) cohort, we recruited consecutive patients with acute chest pain and suspected AMI presenting to the Emergency Department of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany. We compared safety, effectiveness and 12-month incidence of the composite endpoint of all-cause death and myocardial infarction between (i) a single-sampling, dual-marker pathway combining high-sensitivity cardiac troponin I (hs-cTnI) and ultra-sensitive copeptin (us-Cop) at presentation (hs-cTnI ≤ 27 ng/L, us-Cop < 10 pmol/L and low-risk ECG) and (ii) a single-sampling pathway based on one-off hs-cTnI determination at presentation (hs-cTnI < 5 ng/L and low-risk ECG). As a comparator, we used the European Society of Cardiology (ESC) 0/1-h dual-sampling algorithm. RESULTS: We enrolled 1,136 patients (male gender 65%) with median age of 64 years (interquartile range, 51–75). Overall, 228 (20%) patients received a final diagnosis of AMI. The two single-sampling instant rule-out pathways yielded similar negative predictive value (NPV): 97.4% (95%CI: 95.4–98.7) and 98.7% (95%CI: 96.9–99.6) for dual-marker and single hs-cTnI algorithms, respectively (P = 0.11). Both strategies were comparably safe as the ESC 0/1-h dual-sampling algorithm and this was consistent across subgroups of early-comers, low-intermediate risk (GRACE-score < 140) and renal dysfunction. Despite a numerically higher rate of false-negative results, the dual-marker strategy ruled-out a slightly but significantly higher percentage of patients compared with single hs-cTnI determination (37.4% versus 32.9%; P < 0.001). There were no significant between-group differences in 12-month composite outcome. CONCLUSIONS: Instant rule-out pathways based on one-off determination of hs-cTnI alone or in combination with us-Cop are comparably safe as the ESC 0/1 h algorithm for the instant rule-out of AMI, yielding similar prognostic information. Instant rule-out strategies are safe alternatives to the ESC 0/1 h algorithm and allow the rapid and effective triage of suspected AMI in patients with low-risk ECG. However, adding copeptin to hs-cTn does not improve the safety of instant rule-out compared with the single rule-out hs-cTn at very low cut-off concentrations. Frontiers Media S.A. 2022-08-09 /pmc/articles/PMC9395923/ /pubmed/36017085 http://dx.doi.org/10.3389/fcvm.2022.895421 Text en Copyright © 2022 Ricci, Neumann, Rübsamen, Sörensen, Ojeda, Cataldo, Zeller, Schäfer, Hartikainen, Golato, Palermi, Zimarino, Blankenberg, Westermann and De Caterina. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Ricci, Fabrizio
Neumann, Johannes T.
Rübsamen, Nicole
Sörensen, Nils A.
Ojeda, Francisco
Cataldo, Ivana
Zeller, Tanja
Schäfer, Sarina
Hartikainen, Tau S.
Golato, Maria
Palermi, Stefano
Zimarino, Marco
Blankenberg, Stefan
Westermann, Dirk
De Caterina, Raffaele
High-sensitivity troponin I with or without ultra-sensitive copeptin for the instant rule-out of acute myocardial infarction
title High-sensitivity troponin I with or without ultra-sensitive copeptin for the instant rule-out of acute myocardial infarction
title_full High-sensitivity troponin I with or without ultra-sensitive copeptin for the instant rule-out of acute myocardial infarction
title_fullStr High-sensitivity troponin I with or without ultra-sensitive copeptin for the instant rule-out of acute myocardial infarction
title_full_unstemmed High-sensitivity troponin I with or without ultra-sensitive copeptin for the instant rule-out of acute myocardial infarction
title_short High-sensitivity troponin I with or without ultra-sensitive copeptin for the instant rule-out of acute myocardial infarction
title_sort high-sensitivity troponin i with or without ultra-sensitive copeptin for the instant rule-out of acute myocardial infarction
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395923/
https://www.ncbi.nlm.nih.gov/pubmed/36017085
http://dx.doi.org/10.3389/fcvm.2022.895421
work_keys_str_mv AT riccifabrizio highsensitivitytroponiniwithorwithoutultrasensitivecopeptinfortheinstantruleoutofacutemyocardialinfarction
AT neumannjohannest highsensitivitytroponiniwithorwithoutultrasensitivecopeptinfortheinstantruleoutofacutemyocardialinfarction
AT rubsamennicole highsensitivitytroponiniwithorwithoutultrasensitivecopeptinfortheinstantruleoutofacutemyocardialinfarction
AT sorensennilsa highsensitivitytroponiniwithorwithoutultrasensitivecopeptinfortheinstantruleoutofacutemyocardialinfarction
AT ojedafrancisco highsensitivitytroponiniwithorwithoutultrasensitivecopeptinfortheinstantruleoutofacutemyocardialinfarction
AT cataldoivana highsensitivitytroponiniwithorwithoutultrasensitivecopeptinfortheinstantruleoutofacutemyocardialinfarction
AT zellertanja highsensitivitytroponiniwithorwithoutultrasensitivecopeptinfortheinstantruleoutofacutemyocardialinfarction
AT schafersarina highsensitivitytroponiniwithorwithoutultrasensitivecopeptinfortheinstantruleoutofacutemyocardialinfarction
AT hartikainentaus highsensitivitytroponiniwithorwithoutultrasensitivecopeptinfortheinstantruleoutofacutemyocardialinfarction
AT golatomaria highsensitivitytroponiniwithorwithoutultrasensitivecopeptinfortheinstantruleoutofacutemyocardialinfarction
AT palermistefano highsensitivitytroponiniwithorwithoutultrasensitivecopeptinfortheinstantruleoutofacutemyocardialinfarction
AT zimarinomarco highsensitivitytroponiniwithorwithoutultrasensitivecopeptinfortheinstantruleoutofacutemyocardialinfarction
AT blankenbergstefan highsensitivitytroponiniwithorwithoutultrasensitivecopeptinfortheinstantruleoutofacutemyocardialinfarction
AT westermanndirk highsensitivitytroponiniwithorwithoutultrasensitivecopeptinfortheinstantruleoutofacutemyocardialinfarction
AT decaterinaraffaele highsensitivitytroponiniwithorwithoutultrasensitivecopeptinfortheinstantruleoutofacutemyocardialinfarction